Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.
Although T cells are critical for host defense against respiratory fungal infections, they also contribute to the immunopathogenesis of Pneumocystis pneumonia (PcP). However, the precise downstream effector mechanisms by which T cells mediate these diverse processes are undefined. In the current study the effects of immune modulation with sulfasalazine were evaluated in a mouse model of PcP-related Immune Reconstitution Inflammatory Syndrome (PcP-IRIS). Recovery of T cell-mediated immunity in Pneumocystis-infected immunodeficient mice restored host defense, but also initiated the marked pulmonary inflammation and severe pulmonary function deficits characteristic of IRIS. Sulfasalazine produced a profound attenuation of IRIS, with the unexpected consequence of accelerated fungal clearance. To determine whether macrophage phagocytosis is an effector mechanism of T cell-mediated Pneumocystis clearance and whether sulfasalazine enhances clearance by altering alveolar macrophage phagocytic activity, a novel multispectral imaging flow cytometer-based method was developed to quantify the phagocytosis of Pneumocystis in vivo. Following immune reconstitution, alveolar macrophages from PcP-IRIS mice exhibited a dramatic increase in their ability to actively phagocytose Pneumocystis. Increased phagocytosis correlated temporally with fungal clearance, and required the presence of CD4(+) T cells. Sulfasalazine accelerated the onset of the CD4(+) T cell-dependent alveolar macrophage phagocytic response in PcP-IRIS mice, resulting in enhanced fungal clearance. Furthermore, sulfasalazine promoted a TH2-polarized cytokine environment in the lung, and sulfasalazine-enhanced phagocytosis of Pneumocystis was associated with an alternatively activated alveolar macrophage phenotype. These results provide evidence that macrophage phagocytosis is an important in vivo effector mechanism for T cell-mediated Pneumocystis clearance, and that macrophage phenotype can be altered to enhance phagocytosis without exacerbating inflammation. Immune modulation can diminish pulmonary inflammation while preserving host defense, and has therapeutic potential for the treatment of PcP-related immunopathogenesis.
Wang
Jing
J
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Gigliotti
Francis
F
Bhagwat
Samir P
SP
George
Thaddeus C
TC
Wright
Terry W
TW
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002469:Cell Separation / Q000379:methods; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry / Q000379:methods; D054019:Immune Reconstitution Inflammatory Syndrome / Q000276:immunology; D056747:Immunomodulation / Q000187:drug effects* / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects / Q000276:immunology; D016676:Macrophages, Alveolar / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D016513:Mice, SCID; D018613:Microscopy, Confocal; D010587:Phagocytosis / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012460:Sulfasalazine / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine
Am J Respir Cell Mol Biol. 2005 Jun;32(6):490-7
15746433
Cytometry A. 2004 Jun;59(2):237-45
15170603
J Immunol. 1996 Mar 1;156(5):1937-41
8596047
Am J Pathol. 2006 Feb;168(2):466-75
16436661
Am J Respir Crit Care Med. 2004 Aug 15;170(4):408-13
15117741
Drugs. 2005;65(13):1825-49
16114981
J Immunol. 2010 Jan 1;184(1):497-502
19949093
Infect Immun. 2004 Apr;72(4):2140-7
15039336
J Clin Invest. 1999 Nov;104(9):1307-17
10545529
Biochem J. 1992 Feb 15;282 ( Pt 1):197-202
1540135
Am J Pathol. 2007 Sep;171(3):790-9
17640969
Cytometry A. 2006 Aug 1;69(8):852-62
16969805
Infect Immun. 2001 Feb;69(2):758-64
11159965
J Immunol Methods. 1996 Jun 21;193(2):149-56
8699028
Chest. 1993 Sep;104(3):763-9
8396001
Immunity. 2003 Sep;19(3):329-39
14499109
Exp Lung Res. 2003 Sep;29(6):401-12
12888452
Eur J Immunol. 2007 Nov;37 Suppl 1:S9-17
17972350
Int J Exp Pathol. 1991 Oct;72(5):589-98
1742212
Gastroenterology. 2010 Apr;138(4):1395-405
20044996
Chest. 1988 Jan;93(1):60-4
3257184
Int J STD AIDS. 2005 Mar;16(3):252-5
15829028
J Eukaryot Microbiol. 1996 Sep-Oct;43(5):12S
8822820
Mol Biol Cell. 2005 Feb;16(2):824-34
15574879
Arch Intern Med. 1995 Dec 11-25;155(22):2436-41
7503602
Ann Intern Med. 1984 May;100(5):663-71
6231873
Am J Med. 1993 Feb;94(2):216-9
8381584
Drugs. 2004;64(10):1069-89
15139787
Arch Intern Med. 1997 Jul 14;157(13):1501-3
9224230
J Biol Chem. 2003 Jul 4;278(27):25001-8
12716885
Gastroenterology. 2000 Nov;119(5):1209-18
11054378
J Exp Med. 1978 Jan 1;147(1):157-70
342665
Infect Immun. 2004 Mar;72(3):1548-56
14977961
J Clin Invest. 1992 Aug;90(2):673-8
1353767
Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1495-505
17307812
Int J Exp Pathol. 1992 Dec;73(6):709-20
1493101
J Rheumatol. 2006 Feb;33(2):213-8
16358366
Nature. 1991 May 9;351(6322):155-8
1903183
Infect Immun. 1993 May;61(5):1641-9
8478052
Immunology. 2001 Aug;103(4):473-8
11529938
Annu Rev Immunol. 2009;27:451-83
19105661
Am Rev Respir Dis. 1989 Jun;139(6):1336-42
2786359
Bone Marrow Transplant. 2003 Sep;32(5):515-22
12942099
J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95
11917244
J Exp Med. 2005 Apr 18;201(8):1205-15
15824083
J Clin Invest. 1998 Oct 1;102(7):1332-44
9769325
Arch Intern Med. 1995 Jun 12;155(11):1125-8
7763117
Chest. 2000 Sep;118(3):712-20
10988193
Clin Infect Dis. 1993 Nov;17 Suppl 2:S416-22
8274607
J Immunol. 2004 Feb 15;172(4):2511-21
14764724
Dig Dis Sci. 2004 Sep;49(9):1458-60
15481319
Br J Pharmacol. 1999 Dec;128(7):1361-9
10602313
J Immunol. 2008 Apr 1;180(7):4939-47
18354219
J Immunol Methods. 2006 Apr 20;311(1-2):117-29
16563425
J Clin Invest. 1998 Mar 1;101(5):1163-74
9486988
Infect Immun. 2004 Jun;72(6):3147-60
15155616
AIDS. 1991 May;5(5):527-33
1863404
Cytopathology. 1991;2(3):113-20
1718475
Infect Immun. 2004 Nov;72(11):6211-20
15501746
Respir Med. 1995 Apr;89(4):285-90
7597268
Chest. 2005 Sep;128(3):1385-92
16162733
Eur J Immunol. 2002 May;32(5):1282-91
11981815
Am J Respir Crit Care Med. 1995 Apr;151(4):1058-62
7697231
Am Rev Respir Dis. 1989 Nov;140(5):1204-9
2817582
Infect Immun. 1999 Jul;67(7):3452-60
10377126
HIV Med. 2002 Jul;3(3):207-11
12139660
BMC Infect Dis. 2004 Dec 09;4(1):57
15588295
J Immunol. 2004 Jul 1;173(1):21-4
15210754
J Gastroenterol Hepatol. 2005 Jul;20(7):1016-24
15955209
Scand J Infect Dis. 2007;39(6-7):612-4
17577827
J Clin Invest. 1997 May 1;99(9):2110-7
9151783
J Leukoc Biol. 2002 Oct;72(4):790-9
12377949
Clin Infect Dis. 1998 Dec;27(6):1379-85
9868646
Am J Physiol Lung Cell Mol Physiol. 2006 Dec;291(6):L1256-66
16891394
Cytopathology. 1993;4(4):231-6
8400057
Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):512-4
15141339
J Exp Med. 2003 Dec 1;198(11):1677-88
14657220
Chest. 1993 Sep;104(3):756-62
8365286
Infect Immun. 2005 May;73(5):2766-77
15845480
Clin Infect Dis. 1999 Oct;29(4):784-6
10589888
PLoS Pathog. 2010 Jan;6(1):e1000714
20062524
Immunol Invest. 2007;36(5-6):739-61
18161527
J Pathol. 1991 Jun;164(2):175-84
2072217